204 related articles for article (PubMed ID: 33504855)
1. Development of a target identification approach using native mass spectrometry.
Liu M; Van Voorhis WC; Quinn RJ
Sci Rep; 2021 Jan; 11(1):2387. PubMed ID: 33504855
[TBL] [Abstract][Full Text] [Related]
2. Ligand-protein target screening from cell matrices using reactive desorption electrospray ionization-mass spectrometry via a native-denatured exchange approach.
Zheng Q; Ruan X; Tian Y; Hu J; Wan N; Lu W; Xu X; Wang G; Hao H; Ye H
Analyst; 2019 Jan; 144(2):512-520. PubMed ID: 30489587
[TBL] [Abstract][Full Text] [Related]
3. Native Mass Spectrometry in Fragment-Based Drug Discovery.
Pedro L; Quinn RJ
Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
[TBL] [Abstract][Full Text] [Related]
4. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
[TBL] [Abstract][Full Text] [Related]
5. Multiple ligand detection and affinity measurement by ultrafiltration and mass spectrometry analysis applied to fragment mixture screening.
Qin S; Ren Y; Fu X; Shen J; Chen X; Wang Q; Bi X; Liu W; Li L; Liang G; Yang C; Shui W
Anal Chim Acta; 2015 Jul; 886():98-106. PubMed ID: 26320641
[TBL] [Abstract][Full Text] [Related]
6. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
[TBL] [Abstract][Full Text] [Related]
7. Application of the Exactive Plus EMR for automated protein-ligand screening by non-covalent mass spectrometry.
Maple HJ; Scheibner O; Baumert M; Allen M; Taylor RJ; Garlish RA; Bromirski M; Burnley RJ
Rapid Commun Mass Spectrom; 2014 Jul; 28(13):1561-8. PubMed ID: 24861608
[TBL] [Abstract][Full Text] [Related]
8. Drug screening of pharmaceutical discovery compounds by micro-size exclusion chromatography/mass spectrometry.
Wabnitz PA; Loo JA
Rapid Commun Mass Spectrom; 2002; 16(2):85-91. PubMed ID: 11754252
[TBL] [Abstract][Full Text] [Related]
9. Screening of protein-ligand interactions under crude conditions by native mass spectrometry.
Takano K; Arai S; Sakamoto S; Ushijima H; Ikegami T; Saikusa K; Konuma T; Hamachi I; Akashi S
Anal Bioanal Chem; 2020 Jul; 412(17):4037-4043. PubMed ID: 32328689
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometry for fragment screening.
Chan DS; Whitehouse AJ; Coyne AG; Abell C
Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
[TBL] [Abstract][Full Text] [Related]
11. May the Best Molecule Win: Competition ESI Mass Spectrometry.
Laughlin S; Wilson WD
Int J Mol Sci; 2015 Oct; 16(10):24506-31. PubMed ID: 26501262
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of DNA/Ligand interactions by electrospray ionization mass spectrometry.
Brodbelt JS
Annu Rev Anal Chem (Palo Alto Calif); 2010; 3():67-87. PubMed ID: 20636034
[TBL] [Abstract][Full Text] [Related]
13. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy.
Moy FJ; Haraki K; Mobilio D; Walker G; Powers R; Tabei K; Tong H; Siegel MM
Anal Chem; 2001 Feb; 73(3):571-81. PubMed ID: 11217765
[TBL] [Abstract][Full Text] [Related]
14. Probing specific ligand-protein interactions by native-denatured exchange mass spectrometry.
Zheng Q; Tian Y; Ruan X; Chen H; Wu X; Xu X; Wang G; Hao H; Ye H
Anal Chim Acta; 2018 Dec; 1036():58-65. PubMed ID: 30253837
[TBL] [Abstract][Full Text] [Related]
15. Protein-Small Molecule Interactions in Native Mass Spectrometry.
Bennett JL; Nguyen GTH; Donald WA
Chem Rev; 2022 Apr; 122(8):7327-7385. PubMed ID: 34449207
[TBL] [Abstract][Full Text] [Related]
16. Sizing Up Protein-Ligand Complexes: The Rise of Structural Mass Spectrometry Approaches in the Pharmaceutical Sciences.
Eschweiler JD; Kerr R; Rabuck-Gibbons J; Ruotolo BT
Annu Rev Anal Chem (Palo Alto Calif); 2017 Jun; 10(1):25-44. PubMed ID: 28301749
[TBL] [Abstract][Full Text] [Related]
17. Ion mobility-mass spectrometry of intact protein--ligand complexes for pharmaceutical drug discovery and development.
Niu S; Rabuck JN; Ruotolo BT
Curr Opin Chem Biol; 2013 Oct; 17(5):809-17. PubMed ID: 23856053
[TBL] [Abstract][Full Text] [Related]
18. A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline.
Chen X; Qin S; Chen S; Li J; Li L; Wang Z; Wang Q; Lin J; Yang C; Shui W
Sci Rep; 2015 Feb; 5():8361. PubMed ID: 25666181
[TBL] [Abstract][Full Text] [Related]
19. Immobilized fusion protein affinity chromatography combined with HPLC-ESI-Q-TOF-MS/MS for rapid screening of PPARγ ligands from natural products.
Zhu J; Yi X; Liu W; Xu Y; Chen S; Wu Y
Talanta; 2017 Apr; 165():508-515. PubMed ID: 28153290
[TBL] [Abstract][Full Text] [Related]
20. Sliding Window Adduct Removal Method (SWARM) for Enhanced Electrospray Ionization Mass Spectrometry Binding Data.
Kitov PI; Han L; Kitova EN; Klassen JS
J Am Soc Mass Spectrom; 2019 Aug; 30(8):1446-1454. PubMed ID: 31025293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
